HENDERSON, NV / ACCESSWIRE / July 8, 2018 / In order to take a drug to market the cost was estimated to be $2.4 billion. This has caused many biotech firms to enter the device market, rather than drug market.
Medical devices are finding increasing use in the treatment of diseases traditionally targeted with drugs. It is well established that Nervous system disorders are a large and growing challenge. Pills will not save these individuals struggling in pain, which leaves a tremendous opportunity for biomedical engineering to begin solving some of these problems.
These companies are a treat for potential investors: Endonovo Therapeutics, Inc. (ENDV), Geron Corporation (NASDAQ: GERN), Pulse Biosciences, Inc. (PLSE)
Endonovo Therapeutics, Inc. (ENDV)
Market Cap: $13.2M, current share price: $.03
Endonovo Therapeutics is a commercial stage developer of non-invasive medical devices designed to deliver its proprietary Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. Endonovo's Electroceutical Therapy is FDA-Cleared for the palliative treatment of pain and post-surgical edema (swelling) and CE Marked for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. Endonovo's Electroceutical Therapy has CMS National Coverage for the treatment of chronic wounds. The Company's current pipeline of clinical-stage Electroceutical Therapies targets cardiovascular diseases and central nervous system disorders, including ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI) and multiple sclerosis.
Geron Corporation (NASDAQ: GERN)
Market Cap: $614.43M, current share price: $3.55
Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.
Pulse Biosciences, Inc. (PLSE:)
Market Cap: $254.83M, current share price: $15.10
Pulse Biosciences, Inc., a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and sixty one thousand dollars total by Regal Consulting. LLC, for news commentary articles for ENDV. ENDV and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.
For Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspecualtors.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: ACR Communication, LLC
